Faculty Appointments
Patient Care Settings
Cancer, Neurology
Biography
Dr. Mohile completed his residency training at Northwestern University, followed by a fellowship in Neuro-oncology at Memorial Sloan-Kettering Cancer Center. He is certified in Neurology and Neuro-oncology. In 2007, he joined the neurology department at the University of Rochester where he built and fostered the neuro-oncology division and multi-disciplinary brain tumor program. His mission is to teach, elevate clinical care and perform research that extends and improves the lives of patients with brain tumors.
Dr. Mohile sees patients with primary and metastatic brain tumors and is involved in administering chemotherapy, treating seizures and managing side effects of brain tumors and brain tumor therapy. In addition, he does consultations on patients with neurologic complications of cancer or cancer treatments.
Professional Background
Nimish Mohile, MD, MS, FAAN is a Professor of Neurology and Oncology at the University of Rochester and the Ann Aresty Camhi Professor of Neurology. He serves as the Associate Chair for Academic Affairs, Neuro-oncology Division Chief and leads the Neuro-oncology service line. He is a UCNS fellowship program director, serves on the UCNS Certification committee, chairs the American Society of Clinical Oncology Glioma Guidelines Panel and is currently the Chair of the AAN section for Neuro-oncology.
As an Associate Chair for Academic Affairs, he has spearheaded innovative programs that emphasize personal values, identity and reflective work in the professional development of faculty, administrative staff, advanced practice providers and residents. He also directs departmental leadership programs for residents and faculty to develop leadership skills, implement change and develop resilient teams. At the American Academy of Neurology, he serves as the Physician Lead for the Transforming Leaders Program.
Dr. Mohile aspires to help organizations transform into multicultural, antiracist and equitable entities. He is an advocate for incorporating principles of inclusion, diversity, equity, antiracism and social justice into the profession of neurology. He is the Chair of the AAN Diversity Officer’s Group.
Research
His research focuses on developing and testing therapeutic and supportive care interventions to improve and extend the lives of patients with malignant gliomas. He has authored over 50 peer-reviewed publications. He is currently the principal investigator of several industry-sponsored, investigator-initiated and NCI- funded clinical trials. He has developed a body of work that explores the burdens experienced by patients with brain tumors and caregivers, related to hospitalizations, seizures, decision-making and end of life care.
Credentials
Education
2000
MD | St. George's University School of Medicine (Grenada)
Post-doctoral Training & Residency
07/01/2005 - 06/30/2007
Fellowship at Memorial Sloan-Kettering Cancer Center
07/01/2004 - 06/30/2005
Fellowship in Clinical Neurophysiology at Northwestern Memorial Hospital
07/01/2001 - 06/30/2004
Residency in Neurology at Northwestern Memorial Hospital
07/01/2000 - 06/30/2001
Internship in Internal Medicine at Norwalk Hospital
VIEW ALL expand_more
Awards
2015
A. B. Baker Teacher Recognition Award
Sponsor: American Academy of Neurology
2011
SWOG Travel Award Recipient
Sponsor: Southwest Oncology Group
2011
Neurology Faculty Teaching Award
Sponsor: University of Rochester
Location: Rochester, NY
2009
American Neurological Association Junior Academic Scholarship Award
2007
American Society of Clinical Oncology Foundation Merit Award
Sponsor: American Society of Clinical Oncology Foundation
2004
Graduate Medical Education Award for excellence in teaching medical students
2004
AAN Resident Annual Meeting Scholarship
Sponsor: American Academy of Neurology
1996 - 2000
Dean's List
Sponsor: St George's University
Location: Grenada, WI
1994
Dean's List
Sponsor: Duke University
Location: Durham, NC
VIEW ALL expand_more
Clinical Trials
Early Telehealth Visits for Discussion of Advanced Directives for Patients Newly Diagnosed With High Grade Glioma: Impact on Patient Care and Satisfaction
Lead Researcher: Nimish A Mohile
High grade gliomas (HGGs) are rapidly progressive brain tumors resulting in death for most patients between 6 months and 2 years after diagnosis. It is important for patients with HGG to discuss and document their wishes at the end of life. However, many of these patients experience early changes in cognition which impede their decision-making. For this reason, these patients should have early discussions with their providers. However, implementation of this remains challenging in clinical practice.
In this study, we will create an Early STructured Advanced care Referrals by Telehealth (Early START) visit for patients soon after their initial oncology visit. A checklist and pre-visit guide were developed to help guide the visit for both the provider and patient. Providers will receive special training in running these visits. Caregivers and/or family members will be encouraged to participate. Visits will be done using video or telephone and recorded. For patients who do not have access to technology for these visits, it will be provided. After the visit, patients, caregivers and/or family who participated, and providers will fill out surveys to address feasibility of having these extra visits and improve the visits for future. Patients will be followed until death. Caregivers and/or family who participated will be asked about whether end of life was in line with the patient's wishes. We will also use the patient's medical record to assess other aspects of end of life. We will compare end of life outcomes with other similar patients treated at our center.
View Study Details
Genomically-Guided Treatment Trial in Brain Metastases
Lead Researcher: Nimish A Mohile
This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK, PI3K, or KRAS G12C. Medications that target these genes such as abemaciclib, paxalisib, entrectinib and adagrasib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation.
View Study Details
Publications
Journal Articles
1/30/2024
Ranjan S, Leung D, Ghiaseddin AP, Taylor JW, Lobbous M, Dhawan A, Budhu JA, Coffee E, Melnick K, Chowdhary SA, Lu-Emerson C, Kurz SC, Burke JE, Lam K, Patel MP, Dunbar EM, Mohile NA, Peters KB. "Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients." Cancer.. 2024 Jan 30; Epub 2024 Jan 30.
1/10/2024
Jean MJ, Samkoff L, Mohile N. "Management of Paraneoplastic Syndromes in the Era of Immune Checkpoint Inhibitors." Current treatment options in oncology.. 2024 Jan 10; Epub 2024 Jan 10.
2024
Goldlust SA, Nabors LB, Hsu S, Mohile N, Duic PJ, Benkers T, Singer S, Rao M, Cappello L, Silberman SL, Farmer G. "Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma." Neuro-oncology advances.. 2024 6(1):vdae009. Epub 2024 Jan 18.
Books & Chapters
2007
Chapter Title: Principles of Chemotherapy
Book Title: Brain Tumors: Practical Guide to Diagnosis and Treatment
Author List: Abrey LE and Mohile NA
Edited By: Baehring J, Piepmeier J
Published By: Informa Health Care, USA 2007 in New York
2006
Chapter Title: Chemotherapy of Neuronal Tumors
Book Title: Handbook of Brain Tumor Chemotherapy
Author List: Mohile, N.A.; Raizer, J.J.
Edited By: Newton, H.B.
Published By: Elsevier 2006 in Amsterdam: Boston
VIEW ALL PUBLICATIONS
Reviews
At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information.